Cerity Partners
IMRX icon

Cerity Partners’s Immuneering IMRX Stock Holding History

Cerity Partners’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121K Buy
+24,175
New +$122K ﹤0.01% 3178

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Cerity Partners's IMRX Position: Q2 2026 in Review

Cerity Partners opened a new position in Immuneering (IMRX) in Q2 2026: 24,175 shares worth $121K. The stake represents ﹤0.01% of the portfolio and ranks #3178 among its holdings.

112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Cerity Partners held 24,175 shares of Immuneering worth $121K as of Q2 2026.
  • Immuneering was a new Cerity Partners position in Q2 2026.
  • Immuneering made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3178 holding.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.